Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT06177457
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
🇺🇸Yale University/Magnetic Resonance Research Center (MRRC), New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Phase 1, First-in-human Study of VX-828
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 159
- Registration Number
- NCT06154447
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Overland Park, Kansas, United States
Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 810
- Registration Number
- NCT06139692
- Locations
- 🇨🇳
Jinling Hospital, Medical School of Nanjing University, Nanjing, None Selected, China
🇨🇳The General Hospital of Western Theater Command PLA, Chengdu, China
Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- National University of Malaysia
- Target Recruit Count
- 90
- Registration Number
- NCT06111872
- Locations
- 🇲🇾
Hospital Canselor Tuanku Muhriz UKM, Cheras, Kuala Lumpur, Malaysia
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT06111521
- Locations
- 🇺🇸
ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States
A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT06106009
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 28
- Registration Number
- NCT06092931
- Locations
- 🇺🇸
ICON Phase 1 Clinic, Salt Lake City, Utah, United States
Adjuvants With Intrathecal Bupivacaine for Postoperative Analgesia
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 90
- Registration Number
- NCT06082232
Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT06033612
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, Greater London, United Kingdom
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06031454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.